FVFabiola N. Velazquez

Fabiola N. Velazquez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fabiola N. Velazquez has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mechanisms of deoxysphinganine cytotoxicity in lymphoma cells

    by Fabiola N. Velazquez, Karissa J. Lopez, Bahman Khalvatifahlylani, Daniel Canals, Yusuf A. Hannun

  • Open Access

    Deoxysphingolipids activate cGAS-STING1 and enhance antitumor immunity

    by Suchandrima Saha, Fabiola N. Velazquez, Fatemeh Dehpanah, Brianna L. Bergfalk, Samantha Mulkeen, Karissa J. Lopez, Cungui Mao, David C. Montrose

    Deoxysphingolipids (deoxySLs) are a class of non-canonical sphingolipids that can adversely impact mitochondrial function. Mitochondrial disruption can activate the cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING1) pathway, and in turn, promote antitumor immunity. Here, we investigated whether inducing deoxySL accumulation in colon cancer cells drives immune-specific, antitumor effects. We show that depleting serine increased deoxySLs and enhanced immune cell infiltration in colon tumors, in parallel with suppressing tumor growth. Elevating tumor deoxySL levels through mutation of SPT in cells and feeding a high alanine diet to mice exerted similar effects, including immune-mediated tumor growth suppression. Work conducted in multiple in vitro systems identified deoxySLs as key triggers of cGAS-STING1 activation, an effect mediated by mitochondrial release of double-stranded DNA resulting from mitochondrial stress. Collectively, these findings provide the first evidence that deoxySLs can drive antitumor immunity and identify a previously unrecognized metabolic strategy for cancer therapy.


  • Targeting sphingosine kinase 1 in p53KO thymic lymphoma

    by Fabiola N. Velazquez, Jeffrey L. Stith, Leiqing Zhang, Amira M. Allam, John Haley, Lina M. Obeid, Ashley J. Snider, Yusuf A. Hannun

    Sphingosine kinase 1 (SK1) is a key sphingolipid enzyme that is upregulated in several types of cancer, including lymphoma which is a heterogenous group of malignancies. Treatment for lymphoma has improved significantly by the introduction of new therapies; however, subtypes with tumor protein P53 (p53) mutations or deletion have poor prognosis, making it critical to explore new therapeutic strategies in this context. SK1 has been proposed as a therapeutic target in different types of cancer; however, the effect of targeting SK1 in cancers with p53 deletion has not been evaluated yet. Previous work from our group suggests that loss of SK1 is a key event in mediating the tumor suppressive effect of p53. Employing both genetic and pharmacological approaches to inhibit SK1 function in Trp53 KO mice, we show that targeting SK1 decreases tumor growth of established p53KO thymic lymphoma. Inducible deletion of Sphk1 or its pharmacological inhibition drive increased cell death in tumors which is accompanied by selective accumulation of sphingosine levels. These results demonstrate the relevance of SK1 in the growth and maintenance of lymphoma in the absence of p53 function, positioning this enzyme as a potential therapeutic target for the treatment of tumors that lack functional p53.


  • Open Access

    Loss of sphingosine kinase 1 increases lung metastases in the MMTV-PyMT mouse model of breast cancer

    by Fabiola N. Velazquez, Leiqing Zhang, Valentina Viscardi, Carolena Trocchia, Yusuf A. Hannun, Lina M. Obeid, Ashley J. Snider

    Breast cancer is a very heterogeneous disease, and ~30% of breast cancer patients succumb to metastasis, highlighting the need to understand the mechanisms of breast cancer progression in order to identify new molecular targets for treatment. Sphingosine kinase 1 (SK1) has been shown to be upregulated in patients with breast cancer, and several studies have suggested its involvement in breast cancer progression and/or metastasis, mostly based on cell studies. In this work we evaluated the role of SK1 in breast cancer development and metastasis using a transgenic breast cancer model, mouse mammary tumor virus-polyoma middle tumor-antigen (MMTV-PyMT), that closely resembles the characteristics and evolution of human breast cancer. The results show that SK1 deficiency does not alter tumor latency or growth, but significantly increases the number of metastatic lung nodules and the average metastasis size in the lung of MMTV-PyMT mice. Additionally, analysis of Kaplan-Meier plotter of human disease shows that high SK1 mRNA expression can be associated with a better prognosis for breast cancer patients. These results suggest a metastasis-suppressing function for SK1 in the MMTV-PyMT model of breast cancer, and that its role in regulating human breast cancer progression and metastasis may be dependent on the breast cancer type.